Cover Image

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism

The aim of this study was to 1) investigate the effects of 27 CYP3A4 variants on the metabolism of osimertinib and 2) study the interactions between osimertinib and others as well as the underlying mechanism. A recombinant human CYP3A4 enzymatic incubation system was developed and employed to determ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nanyong Gao (Author), Xiaodan Zhang (Author), Xiaoqin Hu (Author), Qihui Kong (Author), Jianping Cai (Author), Guoxin Hu (Author), Jianchang Qian (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
by: Zhize Ye, et al.
Published: (2022)

Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions
by: Qihui Kong, et al.
Published: (2023)

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
by: Sychev DA, et al.
Published: (2015)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
by: Mafuru M, et al.
Published: (2021)

Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis
by: Xianghong Zhao, et al.
Published: (2022)

Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children
by: Kathryn E. Kyler, et al.
Published: (2024)

Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
by: Zhang XY, et al.
Published: (2021)

The impacts of natural product miltirone and the CYP2D6 pharmacogenetic phenotype on fluoxetine metabolism
by: Xiaodan Zhang, et al.
Published: (2024)

Proton pump inhibitors in pediatric practice
by: Anna A. Shilova, et al.
Published: (2023)

Proton Pump Inhibitors and Gastric Cancer
by: Seungkyung Kang, et al.
Published: (2021)

RENAL SAFETY OF PROTON PUMP INHIBITORS
by: A. I. Dyadyk, et al.
Published: (2017)

Proton pump inhibitors usage and the risk of cancer
by: Hubert Wróblewski, et al.
Published: (2021)

Management of laryngopharyngeal reflux with proton pump inhibitors
by: Christina Reimer, et al.
Published: (2008)

Proton-pump inhibitors and risk of renal disease
by: Mahrang Hedaiaty, et al.
Published: (2017)

Proton Pump Inhibitors in the COVID-19 Pandemic
by: T. E. Kugler, et al.
Published: (2022)

Is hypomagnesemia associated with using proton pump inhibitors?
by: Joo-Hark Yi, et al.
Published: (2016)

Proton pump inhibitors overuse - consequences among patients
by: Patrycja Kmiotek, et al.
Published: (2019)

Proton pump inhibitors overuse - consequences among patients
by: Patrycja Kmiotek, et al.
Published: (2019)

The consequences of long-term therapy with proton pump inhibitors
by: Zuzanna Drygała, et al.
Published: (2024)

Proton Pump Inhibitors and Cancer: Current State of Play
by: Marie Bridoux, et al.
Published: (2022)

Exploring and understanding adverse effect of Proton Pump Inhibitors
by: Hoque Majedul M.
Published: (2024)

Can Proton Pump Inhibitors Affect Eradication Therapy?
by: Sung Eun Kim
Published: (2020)

Proton Pump Inhibitor Long-term Prescription, Is It Safe?
by: Tae Ho Kim
Published: (2020)

Proton pump inhibitor deprescription: A rapid review
by: Renata Rodriguez Imparato, et al.
Published: (2022)

The Impact of Sex on the Response to Proton Pump Inhibitor Treatment
by: Holmfridur Helgadottir, et al.
Published: (2023)

An unusual case of proton pump inhibitor induced hyperchromograninemia
by: Kwabena Oware Adu-Gyamfi, et al.
Published: (2019)

Proton-pump inhibitor use amongst patients with severe hypomagnesemia
by: Sherry Seah, et al.
Published: (2023)

CYP2C19 genotypes and osteoporotic fractures in long‐term users of proton pump inhibitors: A hospital‐based study
by: Yi‐Ju Liao, et al.
Published: (2023)

Association between proton pump inhibitors and periodontal disease severity
by: Bhavneet K. Chawla, et al.
Published: (2022)

Proton Pump Inhibitors in IPF: A Call for Clinical Trials
by: Yohannes T. Ghebre, et al.
Published: (2018)

Antiplatelet agents and proton pump inhibitors – personalizing treatment
by: Eugene Lin, et al.
Published: (2010)

Risk of Bacterial Infection from Proton Pump Inhibitor Use
by: Sung Soo Kim, et al.
Published: (2017)

Can proton pump inhibitors cause intestinal inflammation in children?
by: Ben Kang
Published: (2019)

The Effect of Proton Pump Inhibitors on Fracture Formation and Reflection on Care
by: Seda Akutay, et al.
Published: (2021)

Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?
by: Rohit Tayal, et al.
Published: (2023)

Proton pump inhibitors to control phosphorus levels in hemodialysis patients
by: Amineh Hojati
Published: (2025)

The Role of Proton Pump Inhibitors in the Management of Pediatric Eosinophilic Esophagitis
by: Carolina Gutiérrez-Junquera, et al.
Published: (2018)

Irrational proton pump inhibitor use during corticosteroid therapy
by: Rakesh Agarwal, et al.
Published: (2018)

Clinical Intervention Increases Rational Use of Proton Pump Inhibitors in the General Surgery Department
by: Qiying Chen, et al.
Published: (2022)

Proton Pump Inhibitors in Germany: Status Quo of a Growing Market
by: Kate Plehhova, et al.
Published: (2024)